Physician profile
James Malone
NPI 1134225832
$5,444.19
in general payments reported to CMS, 2019-2025
32 companies · $890 in 2025
The $890 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $673 · 2020: $333 · 2021: $678 · 2022: $844 · 2023: $989 · 2024: $1,038 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,917.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $803.23 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $641.93 | 2021-2025 | |
| Pfizer INC. | $439.36 | 2020-2025 | |
| Exact Sciences Corporation | $354.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Shield Therapeutics INC | $228.62 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.29 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $194.41 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $193.53 | 2019-2024 | Farxiga |
| Allergan, INC. | $170.89 | 2019-2020 | |
| Amgen INC. | $156.55 | 2021-2025 | Evenity, Prolia, Prolia |
| Glaxosmithkline, LLC. | $145.38 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $114.44 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.36 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.49 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $93.83 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $80.72 | 2019-2023 | Mounjaro |
| Abbott Laboratories | $74.53 | 2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.81 | 2024-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $50.40 | 2024-2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $41.76 | 2023-2025 | Rexulti, Nuedexta |
| Dexcom, INC. | $39.90 | 2023-2024 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $36.57 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $33.46 | 2022 | |
| Merck Sharp & Dohme LLC | $30.05 | 2020-2022 | |
| Eisai INC. | $28.59 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $26.63 | 2022 | |
| Sanofi-Aventis U.S. LLC | $23.88 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.46 | 2022 | |
| Verona Pharma, INC. | $15.75 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $14.32 | 2023 | Yupelri |
| Dynavax Technologies Corporation | $10.55 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.